Literature DB >> 17112574

Comparative effects of dextromethorphan and dextrorphan on nicotine discrimination in rats.

M Jerry Wright1, Robert E Vann, Thomas F Gamage, M Imad Damaj, Jenny L Wiley.   

Abstract

While the role of dextrorphan and dextromethorphan as N-methyl-d-aspartate (NMDA) receptor antagonists has received considerable research attention, their effects on nicotinic acetylcholine receptors (nAChR) has been less well characterized. Recent in vitro and in vivo research has suggested that these drugs noncompetitively block alpha3beta4*, alpha4beta2, and alpha7 nAChR subtypes and antagonize nicotine's antinociceptive and reinforcing effects. Both drugs were most potent at blocking alpha3beta4* AChR. This study investigated the effects of dextrorphan and dextromethorphan on nicotine's discriminative stimulus effects. Three groups of rats were trained in a two-lever drug discrimination procedure to discriminate 0.4 mg/kg s.c. nicotine from saline. Nicotine dose-dependently substituted for itself in all three groups. In contrast, when dextrorphan (group 1) or dextromethorphan (group 2) were injected i.p., neither substitution for nor antagonism of nicotine was observed for either drug. Since i.p. administration allows substantial metabolism of dextromethorphan to its parent compound dextrorphan, the two drugs were also tested following s.c. administration (group 3). Discrimination results were similar across both routes of administration, in that neither substitution nor antagonism occurred, however, s.c. administration reduced response rates to a much greater extent than did i.p. administration. Previous work suggests that beta2 subunits are crucial for mediation of nicotine's discriminative stimulus effects and may play a role in its reinforcing effects, albeit other research suggests a role for alpha3beta4* nicotinic receptors in the latter. Our results suggest that alpha3beta4* nicotinic receptors do not play a major role in nicotine's discriminative stimulus effects. Further, they suggest that the role of cholinergic mediation of the behavioral effects of dextrorphan and dextromethorphan related to the abuse properties of nicotine may be minimal.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17112574      PMCID: PMC1847596          DOI: 10.1016/j.pbb.2006.09.020

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  35 in total

1.  Dopaminergic and cholinergic involvement in the discriminative stimulus effects of nicotine and cocaine in rats.

Authors:  Rajeev I Desai; David J Barber; Philip Terry
Journal:  Psychopharmacology (Berl)       Date:  2003-04-09       Impact factor: 4.530

2.  Discrimination of agonist-antagonist mixtures: experiments with nicotine plus mecamylamine.

Authors:  E.A. Mariathasan; I.P. Stolerman
Journal:  Behav Pharmacol       Date:  1993-12       Impact factor: 2.293

3.  Analgesic effects of phencyclidine-like drugs in rhesus monkeys.

Authors:  C P France; A M Snyder; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1989-07       Impact factor: 4.030

4.  The role of nicotinic receptor beta-2 subunits in nicotine discrimination and conditioned taste aversion.

Authors:  M Shoaib; J Gommans; A Morley; I P Stolerman; R Grailhe; J-P Changeux
Journal:  Neuropharmacology       Date:  2002-03       Impact factor: 5.250

5.  Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan.

Authors:  Y C Chou; J F Liao; W Y Chang; M F Lin; C F Chen
Journal:  Brain Res       Date:  1999-03-13       Impact factor: 3.252

6.  Dextromethorphan and carbetapentane: centrally acting non-opioid antitussive agents with novel anticonvulsant properties.

Authors:  F C Tortella; J M Musacchio
Journal:  Brain Res       Date:  1986-09-24       Impact factor: 3.252

7.  High affinity [3H]dextrorphan binding in rat brain is localized to a noncompetitive antagonist site of the activated N-methyl-D-aspartate receptor-cation channel.

Authors:  P H Franklin; T F Murray
Journal:  Mol Pharmacol       Date:  1992-01       Impact factor: 4.436

Review 8.  Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists.

Authors:  B Ebert; C Thorkildsen; S Andersen; L L Christrup; H Hjeds
Journal:  Biochem Pharmacol       Date:  1998-09-01       Impact factor: 5.858

9.  Role of training dose in discrimination of nicotine and related compounds by rats.

Authors:  I P Stolerman; H S Garcha; J A Pratt; R Kumar
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

10.  Nicotine place preference in the mouse: influences of prior handling, dose and strain and attenuation by nicotinic receptor antagonists.

Authors:  Sheri D Grabus; Billy R Martin; Sharon E Brown; M Imad Damaj
Journal:  Psychopharmacology (Berl)       Date:  2006-02-04       Impact factor: 4.530

View more
  6 in total

Review 1.  Neuropharmacology of the interoceptive stimulus properties of nicotine.

Authors:  Thomas E Wooters; Rick A Bevins; Michael T Bardo
Journal:  Curr Drug Abuse Rev       Date:  2009-09

2.  Behavioral effects of phencyclidine on nicotine self-administration and reinstatement in the presence or absence of a visual stimulus in rats.

Authors:  Natashia Swalve; Steven T Pittenger; Rick A Bevins; Ming Li
Journal:  Psychopharmacology (Berl)       Date:  2015-04-07       Impact factor: 4.530

3.  Nicotine drug discrimination and nicotinic acetylcholine receptors in differentially reared rats.

Authors:  Charles S Bockman; Wanyun Zeng; Jamie Hall; Beth Mittelstet; Liz Schwarzkopf; Dustin J Stairs
Journal:  Psychopharmacology (Berl)       Date:  2018-02-21       Impact factor: 4.530

4.  Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice.

Authors:  Robert E Vann; Jonathan A Warner; Kristen Bushell; John W Huffman; Billy R Martin; Jenny L Wiley
Journal:  Eur J Pharmacol       Date:  2009-05-23       Impact factor: 4.432

5.  A role for glutamate in subjective response to smoking and its action on inhibitory control.

Authors:  J Nesic; T Duka; J M Rusted; A Jackson
Journal:  Psychopharmacology (Berl)       Date:  2011-02-09       Impact factor: 4.530

6.  Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling.

Authors:  Lu Wang; Du Liang; Xiao Xiong; Yusheng Lin; Jianlin Zhu; Zhimeng Yao; Shuhong Wang; Yi Guo; Yuping Chen; Kyla Geary; Yunlong Pan; Fuyou Zhou; Shegan Gao; Dianzheng Zhang; Sai-Ching Jim Yeung; Hao Zhang
Journal:  Oncogene       Date:  2021-02-18       Impact factor: 9.867

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.